Huanyi Bio

Huanyi Bio (焕一生物, also known as AliveX Biotech) is an AI-driven biotech company founded by Wen Wen, who serves as its founder and CEO . The company operates what it describes as China's first multi-omics computational platform combining AA algorithms with systems immunology data, focused on oncology, autoimmune diseases, and neurological disorders .

In December 2020, Huanyi Bio raised an angel round of tens of millions of RMB led by 5Y Capital (formerly Morningside Capital), with Heart Capital following on . The company said the funds would advance its product pipeline and continue optimizing its AI+ systems immunology platform .

By that time, Huanyi had established deep research partnerships with roughly 30 domestic and international institutions, including PLA General Hospital, China-Japan Friendship Hospital, West China Hospital of Sichuan University, Zhengzhou University First Affiliated Hospital, Oxford University, Tsinghua University, and Shanghai Jiao Tong University, and had accumulated tens of thousands of clinical immunology datasets across disease areas .

5Y Capital, an early investor in the ITBT (IT + biotechnology) sector, has cited Huanyi Bio among the digital healthcare startups it identified and supported in that space .